Studies-Poway

ACRC currently studying treatments developed for a wide variety of indications as well as numerous treatments for conditions affecting both men and women.

ACRC Open Protocol Summaries

INDICATION

AGE CRITERIA

DESCRIPTION

Ulcerative Colitis

18-80 years

A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo, and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis

SLE

18-75 years

A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination with Standard Background Therapy in Patients with Moderate to Severe Systemic Lupus Erythematosus

Crohn’s Disease

16-80 years

A 52-Week, Multicenter, Randomized, Double-Blind, Double-dummy, Placebo, and Active Controlled, Operationally Seamless Phase 2b/3 Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease

SLE

≥ 18 yrs. old

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

RA

≥ 18 yrs. old

A 52 -week, phase 3, multicentre, randomized, double-blind, efficacy and safety comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate.

Heart Failure & HyperKalemia

≥ 18 yrs. old

A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium CyclosilicatE in Heart Failure (PRIORITIZE HF)

Heart Failure

≥ 18 yrs. old

Home-Based Fluid Status Monitoring in Heart Failure Patients Recently Hospitalized for Acute Heart Failure

Heart Failure/Obesity

≥ 18 yrs. old

Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Vitiligo

≥ 18 yrs. old

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

HF & DM

18-75 yrs old

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemOdynamIcally Stable Patients with Type 2 Diabetes POST Worsening Heart Failure

FLU

≥ 18 yrs. old

PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATIENTS TO HOUSEHOLD CONTACTS

FLU

≥ 18 yrs. old

A Multi-Center, Randomized, Double-Blind, And Placebo-Controlled Phase II Clinical Study To Investigate The Safety And Efficacy Of Two Doses Of KT07 Compared To Placebo In Subjects With Acute Uncomplicated Influenza

Atopic Dermatitis

≥ 18 yrs. old

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Gout

≥ 18 yrs. old

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA® (pegloticase) (MIRROR Randomized Controlled Trial [RCT])

Gout

≥ 18 yrs. old

A randomized, double-blinded, placebo-controlled study of the efficacy and safety of DYV700 for reducing pain associated with an acute gout flare.

ACRC (Upcoming) Protocol Summaries

INDICATION

AGE CRITERIA

DESCRIPTION

RA

≥ 18 yrs. old

A Randomized Controlled Pragmatic Phase 3b/4 Study of Bariticinib in Patients with RA

Heart Failure

≥ 18 yrs. old

BENEFITS OF MICROCOR (􀀀CorTM) IN AMBULATORY DECOMPENSATED HEART FAILURE

Sciatica

≥ 18 yrs. old

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.)

PTSD

≥ 18 yrs. old

A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder

Heart Failure and HyperK

≥ 18 yrs. old

A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel-Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)

“We accomplish something collectively, that we could not accomplish SEPARATELY.”

Mission


We thrive to become recognized for our high standards in the world of global healthcare by maintaining our commitment to excellence in clinical trial management services.

VISION


Our mission is to win the trust of our clients to achieve their most
important goals of improving clinical,scientific and commercial results for new and innovative medicines that save lives
and improve quality 
of life.

VALUES


Our core values are simply;
Ethics – Credibility – Quality – Client Focus – Teamwork

Back to Top